Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00721799 · ClinicalTrials.gov registry record · Phase 2
F-18 Fluorothymidine PET Imaging for Early Evaluation of Response to Therapy in Head & Neck Cancer Patients
A Phase 2 study of Head and Neck Neoplasms and Oropharyngeal Neoplasms, sponsored by University of Iowa.
- Completed
- Registry status
- Phase 2
- Development phase
- 33
- Enrollment target
- 1
- Study location
NCT00721799 is a Phase 2 study of Head and Neck Neoplasms and Oropharyngeal Neoplasms that has completed, run by University of Iowa. The registered enrollment target is 33 participants, below the 264-participant average among 23 other Head and Neck Neoplasms trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00721799, a Phase 2 study of Head and Neck Neoplasms and Oropharyngeal Neoplasms, has completed, sponsored by University of Iowa.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 33 participants
- Enrollment target
- 1
- Study location
Study Summary
This is an imaging protocol only, not a therapeutic study. The primary goal of the proposed study is to examine the utility of a new imaging study, Positron Emission Tomography with F-18 Fluorothymidine (FLT PET), in the early treatment evaluation of head and neck cancer. FLT uptake in the tumor correlates with the rate of cell proliferation. It is therefore hoped that changes in tumor FLT uptake after therapy will reflect change in the number of actively dividing tumor cells and will provide early assessment of treatment response. Research subjects will undergo one PET scan with FLT. The scan is done prior to any therapeutic intervention (radiation or chemotherapy) can be obtained up to 30 days prior to the start of therapy. The uptake of FLT in the tumor will be analyzed to see if it can be used as a predictor of treatment efficacy and/or outcome. There is an optional biopsy component to this study. Should the attending physicians (primarily the otolaryngologists) believe that the subject can safely undergo an outpatient biopsy, and the subject agrees, a biopsy is performed. The biopsy will be done within 30 days prior to treatment, similar to FLT PET scans. Tissue from the biopsy will be analyzed for markers of cellular proliferation and these markers will be correlated with the findings of FLT PET scan. There will be a 2-year clinical follow-up to assess for treatment outcomes, local control, and overall survival.
Conditions Studied
Interventions
- DRUG 18F-Fluorothymidine PET scan
Study Locations (1)
Iowa
- University of Iowa Hospitals and Clinics - Iowa City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2008-03-01 |
| Est. Completion | 2014-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00721799
The ClinicalTrials.gov registry entry for NCT00721799 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 264-participant average among 23 other Head and Neck Neoplasms trials with a reported enrollment target (87% lower). The listed sponsor is University of Iowa, which has 228 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Head and Neck Neoplasms appearing as the primary indexed condition, and to 1 intervention - of which 18F-Fluorothymidine PET scan is the first listed.
NCT00721799 reports 1 study location spanning 1 distinct geographic area - top geographies include Iowa.
Frequently Asked Questions
What is clinical trial NCT00721799 about?
NCT00721799 is a clinical study titled "F-18 Fluorothymidine PET Imaging for Early Evaluation of Response to Therapy in Head & Neck Cancer Patients". This is an imaging protocol only, not a therapeutic study. The primary goal of the proposed study is to examine the utility of a new imaging study, Positron Emission Tomography with F-18 Fluorothymidine (FLT PET), in the early treatment evaluation of head and neck cancer. FLT uptake in the tumor co...
What is the current status of trial NCT00721799?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 33 participants. The study started on 2008-03-01. Estimated completion is 2014-12-31.
What conditions does trial NCT00721799 study?
This clinical trial studies the following conditions: Head and Neck Neoplasms, Oropharyngeal Neoplasms, Mouth Neoplasms, Laryngeal Neoplasms.
What interventions are being tested in trial NCT00721799?
The interventions under investigation include: 18F-Fluorothymidine PET scan (DRUG).
Who is sponsoring clinical trial NCT00721799?
This trial is sponsored by University of Iowa, which has 228 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00721799 being conducted?
This trial has 1 study location across Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Head and Neck Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Pembrolizumab in Combination With Chemotherapy for Head and Neck Cancer
RECRUITING · Phase 2
-
A Study of Decreasing Radiation Therapy and Chemotherapy in People With Head and Neck Cancer
RECRUITING · Phase 2
-
A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2
ACTIVE NOT RECRUITING · Phase 2
-
Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
ACTIVE NOT RECRUITING · Phase 2
-
P53 Mutational Status and cf HPV DNA for the Management of HPV-associated OPSCC
COMPLETED · Phase 2
-
Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma
COMPLETED · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.